

Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

<https://marketpublishers.com/r/P16D0C0E9865EN.html>

Date: February 2026

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: P16D0C0E9865EN

Abstracts

The Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:

Major Highlights

This report delivers a comprehensive overview of the Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

PSORIATIC ARTHRITIS PIPELINE ANALYSIS

- Psoriatic arthritis (PsA) is an inflammatory condition that causes inflammation of joints. Psoriatic arthritis affects both the skin and the musculoskeletal system.
- Musculoskeletal symptoms are joint pain, tenderness, morning stiffness, swelling, reduction in joint movement; skin symptoms like separation on the nail bed, reddening and thickness of the skin; other symptoms include general fatigue, inflammation of the membrane lining the eyelid.
- Psoriatic arthritis mainly affects the people, who are affected with psoriasis, a skin disease. This is due to the degeneration of the cartilages present in the joints.
- Psoriasis is indicated by scaly red and white skin patches, which will affect any joint in the body such as scalp, elbows, knees, including the spine and others. People with psoriatic arthritis are more likely to be prone to high blood pressure, heart disease, high cholesterol, and diabetes.
- Change of lifestyle such as limiting alcohol intake, weight management, physical exercise, etc. may also help in the treatment process.
- Psoriatic patients are at higher risk of developing other clinical conditions including CVD and other non-communicable diseases.
- The psoriatic arthritis is categorized into asymmetric psoriatic arthritis, symmetric psoriatic arthritis, distal interphalangeal predominant (DIP) psoriatic arthritis, spondylitis, and arthritis mutilans.
- Treatment for psoriatic arthritis depends on its asperity. Various prescribed drugs over-the-counter (OTC) drugs are available for treatment. Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, Non-steroidal drugs, and various biologics.
- Biologics majorly works by stopping the inflammatory condition. Tumor necrosis factor (TNF) and interleukin (IL) inhibitors are mostly used to treat psoriatic arthritis. The current research trend depicts that more emphasis is given on enzyme inhibitors, as TNF alpha is one of the enzymes showing promising results in arthritis. Biosimilar TNF alpha inhibitors present a more significant challenge to broader uptake of Cosentyx and Taltz. The companies are developing new biologics based on IL-17 inhibitors.
- The psoriatic arthritis community has welcomed the recent label update approval of Novartis' IL-17 inhibitor, Cosentyx. Humira is the preferred biologic to treat psoriatic arthritis due to its efficacy in the skin and joint symptoms.
- The drug shows the highest clinical efficacy of any biologic approved. The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly's Taltz (ixekizumab), AstraZeneca's Lumicef (brodalumab) and Celgene's oral therapy Otezla (apremilast). Taltz and Lumicef are expected to emerge as the leading drugs in the psoriatic market.

- Several drugs are into clinical testing which depicts the possibility of discovering new molecules with maximum activity and minimum side effects.
- The rise in the incidence of psoriatic arthritis increased awareness of healthcare professional and new product launch is said to drive the global psoriatic arthritis (PsA) treatment market during the forecast period.
- Whereas inadequate access to health care, cost, and availability of essential medicines and the lack of standardized tools for diagnosis and treatment will hamper the growth of global psoriatic arthritis (PsA) treatment market.

I would like to order

Product name: Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/P16D0C0E9865EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P16D0C0E9865EN.html>